Induced Angiogenesis by Genic Therapy With VEGF165 in Advanced Ischemic Cardiomyopathy - Historical Controlled Trial

Instituto de Cardiologia do Rio Grande do Sul1 site in 1 country20 target enrollmentNovember 2007

ConditionsIschemic Cardiopathy

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Ischemic Cardiopathy
Sponsor: Instituto de Cardiologia do Rio Grande do Sul
Enrollment: 20
Locations: 1
Primary Endpoint: Clinical finds
Last Updated: 17 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Human Vascular Endothelial Grown Factor 165 (hVEGF165) administration is promising therapy induces a new vessels, arterioles and capillaries in regions whose revascularization surgery is not possible by direct or by percutaneous angioplasty. This study aims to evaluate the clinical effects and safety of gene therapy with hVEGF165 in patients with advanced coronary artery disease.

Registry

clinicaltrials.gov

Start Date

November 2007

End Date

May 2009

Last Updated

17 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Instituto de Cardiologia do Rio Grande do Sul

Eligibility Criteria

Inclusion Criteria

•Diagnosis coronary artery disease and symptomatic, despite optimal pharmacologic therapy
•Left ventricular dysfunction - left ventricular ejection fraction between 60% and 25% by echocardiogram
•Non-conventional revascularization, as seen by cineangiocardiography, attested by interventional cardiologist and cardiac surgeon
•Age below 75 years
•Absence of neoplasm